GH Research logo
GH Research
GHRS | NASDAQ
Chart Builder DCF Calculator
$18.75
-$0.35 (-1.83%)
At close: Nov 16, 2026, 4:00 PM ET
$18.75
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

GH Research Company Profile

Company profile explained

Company Profile

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.

Key Executives

Name Position
Velichka Valcheva Chief Executive Officer
Aaron Cameron Chief Operating Officer
Florian Schonharting Co-Founder & Non-Executive Chairman of the Board
Julie Ryan Vice President of Finance
Magnus Halle Co-Founder & MD of Ireland

Latest SEC Filings

Date Type Title
Oct 09, 2026 6-K Filing
Sep 11, 2026 6-K Filing
Sep 09, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 4 Filing
Aug 13, 2026 4 Filing
Aug 13, 2026 4 Filing
Aug 06, 2026 6-K Filing
Jun 26, 2026 6-K Filing
View All SEC Filings ➞
GH Research
GH Research logo
Country Ireland
IPO Date Jun 25, 2021
Industry Biotechnology
Sector Healthcare
Employees 73
CEO Velichka Valcheva

Contact Details

Joshua Dawson House Dublin, DU D02 RY95 Ireland

Stock Details

Ticker Symbol GHRS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001855129
CUSIP Number G3855L106
ISIN Number IE000GID8VI0
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.